Fernanda Faião-Flores

Fernanda Faião-Flores

Auto-generated profile, based on publicly available information

Fernanda Faião-Flores

Department of Clinical Chemistry & Toxicology, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
OCOrlando Chiarelli-Neto
Orlando Chiarelli-Neto
AFAlan Silva Ferreira
Alan Silva Ferreira
WMWaleska Kerllen Martins
Waleska Kerllen Martins
CPChristiane Pavani
Christiane Pavani
DSDivinomar Severino
Divinomar Severino
Mauricio  BaptistaMauricio Baptista
Mauricio Baptista
Protecting human skin from sun exposure is a complex issue that involves unclear aspects of the interaction between light and tissue. A persistent misconception is that visible light is safe for the skin, although several lines of evidence suggest otherwise. Here, we show that visible light can damage melanocytes through melanin photosensitization and singlet oxygen (1O2) generation, thus decreasing cell viability, increasing membrane permeability, and causing both DNA photo-oxidation and necro-apoptotic cell death. UVA (355 nm) and visible (532 nm) light photosensitize 1O2 with similar yields, and pheomelanin is more efficient than eumelanin at generating 1O2 and resisting photobleaching. Although melanin can protect against the cellular damage induced by UVB, exposure to visible light leads to pre-mutagenic DNA lesions (i.e., Fpg- and Endo III-sensitive modifications); these DNA lesions may be mutagenic and may cause photoaging, as well as other health problems, such as skin cancer.

17 October 2016 in Oncogene
Verified
Journal Article
Open access
FFF Faião-Flores
F Faião-Flores
DAD K Alves-Fernandes
D K Alves-Fernandes
PPP C Pennacchi
P C Pennacchi
SSS Sandri
S Sandri
AVA L S A Vicente
A L S A Vicente
SMSilvya Maria-Engler
Silvya Maria-Engler
BRAF inhibitor (BRAFi) therapy for melanoma patients harboring the V600E mutation is initially highly effective, but almost all patients relapse within a few months. Understanding the molecular mechanisms underpinning BRAFi-based therapy is therefore an important issue. Here we identified a previously unsuspected mechanism of BRAFi resistance driven by elevated Hedgehog (Hh) pathway activation that is observed in a cohort of melanoma patients after vemurafenib treatment. Specifically, we demonstrate that melanoma cell lines, with acquired in vitro-induced vemurafenib resistance, show increased levels of glioma-associated oncogene homolog 1 and 2 (GLI1/GLI2) compared with naïve cells. We also observed these findings in clinical melanoma specimens. Moreover, the increased expression of the transcription factors GLI1/GLI2 was independent of canonical Hh signaling and was instead correlated with the noncanonical Hh pathway, involving TGFβ/SMAD (transforming growth factor-β/Sma- and Mad-related family) signaling. Knockdown of GLI1 and GLI2 restored sensitivity to vemurafenib-resistant cells, an effect associated with both growth arrest and senescence. Treatment of vemurafenib-resistant cells with the GLI1/GLI2 inhibitor Gant61 led to decreased invasion of the melanoma cells in a three-dimensional skin reconstruct model and was associated with a decrease in metalloproteinase (MMP2/MMP9) expression and microphthalmia transcription factor upregulation. Gant61 monotherapy did not alter the drug sensitivity of naïve cells, but could reverse the resistance of melanoma cells chronically treated with vemurafenib. We further noted that alternating dosing schedules of Gant61 and vemurafenib prevented the onset of BRAFi resistance, suggesting that this could be a potential therapeutic strategy for the prevention of therapeutic escape. Our results suggest that targeting the Hh pathway in BRAFi-resistant melanoma may represent a viable therapeutic strategy to restore vemurafenib sensitivity, reducing or even inhibiting the acquired chemoresistance in melanoma patients.

1 September 2016 in Pharmacological Research
Verified
Journal Article
Closed access
SSSilvana Sandri
Silvana Sandri
FFFernanda Faião-Flores
Fernanda Faião-Flores
MTManoela Tiago
Manoela Tiago
PPPaula Comune Pennacchi
Paula Comune Pennacchi
RMRenato Ramos Massaro
Renato Ramos Massaro
SMSilvya Maria-Engler
Silvya Maria-Engler

1 September 2015 in Tissue Engineering Part A
Verified
Journal Article
Closed access
PPPaula Comune Pennacchi
Paula Comune Pennacchi
MAMaíra Estanislau Soares de Almeida
Maíra Estanislau Soares de Almeida
OGOctávio Luís Alves Gomes
Octávio Luís Alves Gomes
FFFernanda Faião-Flores
Fernanda Faião-Flores
MCMaria Clara de Araújo Crepaldi
Maria Clara de Araújo Crepaldi
SMSilvya Maria-Engler
Silvya Maria-Engler
The advanced glycation end products (AGEs) of proteins are common factors in the pathophysiology of a number of disorders related to aging. The skin generation of AGEs occurs mainly through nonenzymatic glycation reactions of extracellular matrix (ECM) proteins in the dermis. The AGEs have been touted as one of the factors responsible for healing impairment and loss of elasticity of healing skin, affecting growth, differentiation, and cellular motility, as well as cytokines response, metalloproteinases expression, and vascular hemostasis. In this study, we generated an in vitro full-thickness reconstructed skin based on a glycated collagen matrix dermal compartment to evaluate the effects of glycation on dermal ECM and ultimately on the epidermis. Epidermal differentiation and stratification patterns and the glycation-induced ECM changes were evaluated by histology, immunohistochemistry, and mRNA levels. In this study, we reported for the first time that changes in the dermal matrix caused by collagen I in vitro glycation processes also affect the epidermal compartment. We demonstrated that glycation of collagen induces expression of carboxymethyllysine in dermal and epidermal compartments and, consequently, an aging phenotype consisting of poor stratification of epidermal layers and vacuolization of keratinocyte cytoplasm. Increased expression of cell–cell adhesion markers, such as desmoglein and E-cadherin in glycated skins, is observed in the stratum spinosum, as well as an increased compression of dermal collagen matrix. We also submitted our 3D model of reconstructed glycated skin to screening of anti-AGE molecules, such as aminoguanidine, which prevented the glycated morphological status. Controlled human studies investigating the effects of anti-AGE strategies against skin aging are largely missing. In this context, we proposed the use of skin equivalents as an efficient model to investigate cellular interactions and ECM changes in the aging skin, and to elucidate the role of anti-AGEs molecules in this process.

1 December 2016 in Biochemical Pharmacology
Verified
Journal Article
Closed access
MEMichael F. Emmons
Michael F. Emmons
FFFernanda Faião-Flores
Fernanda Faião-Flores
KSKeiran S.M. Smalley
Keiran S.M. Smalley

1 May 2017 in Pharmacological Research
Verified
Journal Article
Closed access
RMR.R. Massaro
R.R. Massaro
FFF. Faião-Flores
F. Faião-Flores
VRV.W. Rebecca
V.W. Rebecca
SSS. Sandri
S. Sandri
DAD.K. Alves-Fernandes
D.K. Alves-Fernandes
SMSilvya Maria-Engler
Silvya Maria-Engler